In:
FEBS Letters, Wiley, Vol. 586, No. 20 ( 2012-10-19), p. 3639-3644
Abstract:
► Anti‐metastatic efficacy of TF14016, a CXCR4 inhibitor, on SCLC was examined. TF14016 treatment significantly suppressed pulmonary metastases of SCLC cells in mice. ► VEGF expression in metastasized SCLC cells was suppressed by TF14016‐treatment. ► CD31‐positive microvessels in metastatic foci were reduced by TF14016 treatment. ► CXCR4 could be a target for anti‐metastatic and anti‐angiogenic therapy in SCLC.
Type of Medium:
Online Resource
ISSN:
0014-5793
,
1873-3468
DOI:
10.1016/j.febslet.2012.08.011
Language:
English
Publisher:
Wiley
Publication Date:
2012
detail.hit.zdb_id:
212746-5
detail.hit.zdb_id:
1460391-3
SSG:
12